In this study, oral application of PXS-5505, a novel pan-lysyl oxidase inhibitor currently in clinical development for myelofibrosis (NCT04676529) and hepatocellular carcinoma (NCT05109052), effectively diminished fibrosis in each model and, therefore, represents an exciting new therapeutic approach for the treatment for SSc. This evidence concerns the gene LOX and myelofibrosis.